GlassScriptPhysician profile
Irina Zaydman
NPI 1891796637
$765.17
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $317 · 2021: $167.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $174.43 | 2020-2021 | |
| Pfizer INC. | $147.03 | 2019-2021 | |
| Tris Pharma INC | $80.70 | 2019-2020 | |
| Genentech USA, INC. | $65.15 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $54.18 | 2019-2020 | |
| Cranial Technologies, INC | $47.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $42.01 | 2019-2020 | |
| Neos Therapeutics, LP | $40.59 | 2019-2020 | |
| Adlon Therapeutics L.P. | $40.28 | 2020 | |
| Sanofi Pasteur INC. | $30.06 | 2020-2021 | |
| Shire North American Group INC | $15.77 | 2019 | |
| Medline Industries LP | $14.70 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $13.02 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Zaydman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.